AV-380-22-102: A Dose Escalation Study of GDF-15 Inhibitor AV-380 in Metastatic Cancer Patients with Cachexia
Condition: Cachexia
Sponsor: AVEO Pharmaceuticals, Inc.
Full Title
AV-380-22-102: A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels
Study Treatment
Intravenous GDF-15 inhibitor AV-380
Eligibility/Info
Advanced or metastatic cancer currently being treated with standard of care systemic therapy.
Must have cachexia as defined by the Fearon criteria as one of:
- Weight loss >5% over past 6 months (in absence of simple starvation), or
- BMI < 20 kg/m2 and any degree of weight loss >2%, or
- Sarcopenia and >2% weight loss
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
